Edwards Lifesciences
EWWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $105.23 (close on November 18) and with the other assumptions at their starting point, Edwards Lifesciences's sales would need to grow 20.1% a year for ten years; over its last decade, the median was 11.9%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 2,494 | — | 27.6% |
| 12/2016 | 2,964 | 18.8% | 27.3% |
| 12/2017 | 3,435 | 15.9% | 33.5% |
| 12/2018 | 3,723 | 8.4% | 22.0% |
| 12/2019 | 4,348 | 16.8% | 28.2% |
| 12/2020 | 4,386 | 0.9% | 22.6% |
| 12/2021 | 5,232 | 19.3% | 34.4% |
| 12/2022 | 4,464 | −14.7% | 36.4% |
| 12/2023 | 5,010 | 12.2% | 28.9% |
| 12/2024 | 5,440 | 8.6% | 28.3% |
| 12/2025 | 6,068 | 11.5% | 23.4% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Edwards Lifesciences files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 11.5% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 28.3% of sales.
- Working capital needed to grow: $13.9 per $100 of new sales.
- Capital spending: 5.0% of sales.
- Stock pay to employees: 2.4% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- It has more cash than debt.
- It makes $28 of operating profit for every $100 it sells, before stock pay; the median is $18.
- It sold more than the year before in 9 of the last 10 years.
- It generated free cash flow in each of the last 5 years.
Against
- It ties up $14 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
- It is one of the smallest in grinboss: it sells $6.1 billion a year; the median is $15.1 billion.
- Its margin jumps from one year to the next: 5.7 points on average, and up to 11.8 in a single year; the median is 2.8 points.
- Its capital spending takes 5.0% of its sales every year, more than the median (3.3%).
Next results: February 9, 2027.
Other companies in its sector (Health Care)
GE HealthCare (GEHC) · Gilead Sciences (GILD) · HCA Healthcare (HCA) · Henry Schein (HSIC) · Idexx Laboratories (IDXX) · Illumina, Inc. (ILMN) · Incyte (INCY) · IQVIA (IQV) · All companies
Loading the model…